JP2024524527A - がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体 - Google Patents

がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体 Download PDF

Info

Publication number
JP2024524527A
JP2024524527A JP2024500088A JP2024500088A JP2024524527A JP 2024524527 A JP2024524527 A JP 2024524527A JP 2024500088 A JP2024500088 A JP 2024500088A JP 2024500088 A JP2024500088 A JP 2024500088A JP 2024524527 A JP2024524527 A JP 2024524527A
Authority
JP
Japan
Prior art keywords
antibody
bispecific antibody
tumor
intact
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500088A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023280880A5 (https=
JP2024524527A5 (https=
Inventor
リンドホーファー、ホルスト
ルフ、ペーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trion Research GmbH
Original Assignee
Trion Research GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21184105.1A external-priority patent/EP4116330A1/en
Application filed by Trion Research GmbH filed Critical Trion Research GmbH
Publication of JP2024524527A publication Critical patent/JP2024524527A/ja
Publication of JPWO2023280880A5 publication Critical patent/JPWO2023280880A5/ja
Publication of JP2024524527A5 publication Critical patent/JP2024524527A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024500088A 2021-07-05 2022-07-05 がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体 Pending JP2024524527A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21183796 2021-07-05
EP21183796.8 2021-07-05
EP21184105.1A EP4116330A1 (en) 2021-07-05 2021-07-06 Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
EP21184105.1 2021-07-06
PCT/EP2022/068634 WO2023280880A1 (en) 2021-07-05 2022-07-05 Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2024524527A true JP2024524527A (ja) 2024-07-05
JPWO2023280880A5 JPWO2023280880A5 (https=) 2025-05-12
JP2024524527A5 JP2024524527A5 (https=) 2025-05-12

Family

ID=82656531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500088A Pending JP2024524527A (ja) 2021-07-05 2022-07-05 がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体

Country Status (4)

Country Link
US (1) US20240239916A1 (https=)
EP (1) EP4330289A1 (https=)
JP (1) JP2024524527A (https=)
WO (1) WO2023280880A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
EP4684803A1 (en) 2024-07-25 2026-01-28 CeMM - Forschungszentrum für Molekulare Medizin GmbH Antibody conjugated chemical inducers of degradation of rbm39 and therapeutic uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
CA2414148A1 (en) * 2002-12-30 2004-06-30 William Herman Targeted ligands
WO2013189516A1 (en) * 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
US11820832B2 (en) * 2014-07-25 2023-11-21 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
TWI823906B (zh) * 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法

Also Published As

Publication number Publication date
EP4330289A1 (en) 2024-03-06
US20240239916A1 (en) 2024-07-18
WO2023280880A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
JP2024524527A (ja) がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体
AU2014351308B2 (en) Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
JP7457007B2 (ja) 二重作用ＣＤ１ｄ免疫グロブリン
US20260001964A1 (en) Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof
CN104395344B (zh) 抗b7-h6抗体、融合蛋白及其使用方法
JP5851419B2 (ja) ヘテロダイマー結合タンパク質およびその使用
CN107847587B (zh) Cd30×cd16抗体与pd-1拮抗剂的联合药物
US20210024630A1 (en) Guidance and navigation control proteins and method of making and using thereof
TW201904997A (zh) 引導及導航控制蛋白質以及彼之製造及使用方法
JP2019509055A (ja) 多特異性免疫調節抗原結合構築物
TW202535924A (zh) 抗ｄｌｌ３嵌合抗原受體及其用途
JP2018503399A (ja) 多特異性免疫調節抗原結合構築物
CA2457143A1 (en) In situ immunization
US20250101104A1 (en) Bispecific molecule with tunable affinity to a targeted antigen
JP2026506647A (ja) 多重特異性γδＴＣＲ抗体を含む組み合わせ療法
WO2015075710A1 (en) Compositions comprising anti-ceacam1 antibodies, lymphocyte activating agents and activated lymphocytes for cancer therapy
WO2024085166A1 (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
CN117597366A (zh) 与肿瘤相关抗原结合的多特异性抗体在治疗癌症时不引起或减少神经疼痛
EP4116330A1 (en) Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
WO2023199927A1 (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用
BR122022024159B1 (pt) Uso de um anticorpo monoclonal para ceacam1 humana e de um anticorpo monoclonal para pd-l1 humana ou de um fragmento de ligação ao antígeno do mesmo para tratar câncer
BR112016010557B1 (pt) Uso de um anticorpo monoclonal para ceacam1 humana, ou um fragmento de ligação ao antígeno do mesmo e um anticorpo monoclonal para pd-1 humana ou um fragmento de ligação ao antígeno do mesmo e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250430

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421